Ribociclib for HR-Positive, Advanced Breast Cancer

被引：16
|
作者：
Araki, Kazuhiro [1 ]
Miyoshi, Yasuo [1 ]
机构：
[1] Hyogo Coll Med, Nishinomiya, Hyogo, Japan
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2017年 / 376卷 / 03期
关键词：
KINASE; 4/6; INHIBITOR; PALBOCICLIB; COMBINATION;
D O I：
10.1056/NEJMc1615255
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：288 / 288
页数：1
相关论文
共 50 条
  • [1] Ribociclib for HR-Positive, Advanced Breast Cancer REPLY
    Hortobagyi, Gabriel N.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (03): : 289 - 289
  • [2] Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
    Hortobagyi, G. N.
    Stemmer, S. M.
    Burris, H. A.
    Yap, Y. -S.
    Sonke, G. S.
    Paluch-Shimon, S.
    Campone, M.
    Blackwell, K. L.
    Andre, F.
    Winer, E. P.
    Janni, W.
    Verma, S.
    Conte, P.
    Arteaga, C. L.
    Cameron, D. A.
    Petrakova, K.
    Hart, L. L.
    Villanueva, C.
    Chan, A.
    Jakobsen, E.
    Nusch, A.
    Burdaeva, O.
    Grischke, E. -M.
    Alba, E.
    Wist, E.
    Marschner, N.
    Favret, A. M.
    Yardley, D.
    Bachelot, T.
    Tseng, L. -M.
    Blau, S.
    Xuan, F.
    Souami, F.
    Miller, M.
    Germa, C.
    Hirawat, S.
    O'Shaughnessy, J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (18): : 1738 - 1748
  • [3] Preclinical model of Ribociclib resistance in HR-positive breast cancer
    Aske, Jennifer Carlson
    De, Pradip
    Dey, Nandini
    CANCER RESEARCH, 2022, 82 (12)
  • [4] Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer
    Duso, Bruno Achutti
    Trapani, Dario
    Viale, Giulia
    Criscitiello, Carmen
    D'Amico, Paolo
    Belli, Carmen
    Mazzarella, Luca
    Locatelli, Marzia
    Minchella, Ida
    Curigliano, Giuseppe
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (03) : 299 - 305
  • [5] Ribociclib in HR-positive, HER2-negative breast cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2016, 17 (11): : E482 - E482
  • [6] Everolimus in HR-Positive Advanced Breast Cancer
    Tartarone, Alfredo
    Lerose, Rosa
    Aieta, Michele
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (18): : 1739 - 1739
  • [7] ECONOMIC ASSESSMENT OF RIBOCICLIB FOR THE TREATMENT OF POSTMENOPAUSAL PATIENTS WITH ADVANCED BREAST CANCER HR-POSITIVE, HER2-NEGATIVE
    Velasquez, M.
    Medina, Bustos L.
    Chacon, Zagarra C.
    Rojas, R.
    VALUE IN HEALTH, 2022, 25 (01) : S84 - S84
  • [8] Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer (vol 375, pg 1738, 2016)
    Burris, Howard A.
    Arteaga, Carlos L.
    Yardley, Denise
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (26): : 2582 - 2582
  • [9] Everolimus Approved for HR-Positive Breast Cancer
    不详
    CANCER DISCOVERY, 2012, 2 (09) : 756 - 756
  • [10] Real world experience with exemestane and everolimus for advanced HR-positive breast cancer.
    Wang, Ying
    Le, Dan
    Camateros, Pierre
    Lohrisch, Caroline A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345